Healthcare [ 10/13 ] | Biotechnology [ 65/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.71 Increased by +22.83% | -0.68 Decreased by -4.41% |
| Aug 11, 23 | -0.6 Increased by +22.08% | -0.63 Increased by +4.76% |
| May 15, 23 | -0.55 Increased by +25.68% | -0.67 Increased by +17.91% |
| Mar 17, 23 | -0.49 Increased by +47.31% | -0.8 Increased by +38.75% |
| Nov 4, 22 | -0.92 Decreased by -31.43% | -0.74 Decreased by -24.32% |
| Aug 4, 22 | -0.77 Increased by +7.23% | -0.86 Increased by +10.47% |
| May 6, 22 | -0.74 Decreased by -72.09% | -0.8 Increased by +7.5% |
| Feb 25, 22 | -0.93 Decreased by -8.14% | -0.82 Decreased by -13.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -39.66 M Decreased by -13.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -31.08 M Decreased by -14.23% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -23.37 M Increased by +10.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -20.48 M Increased by +36.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -34.99 M Decreased by -43.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -27.21 M Increased by +5.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -26.01 M Decreased by -72.35% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -32.42 M Decreased by -9.13% | Decreased by N/A% Decreased by N/A% |
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.